Upgrade to SI Premium - Free Trial

IMAX Corporation Reports Fourth-Quarter And Full-Year 2017 Results

February 27, 2018 4:05 PM

NEW YORK, Feb. 27, 2018 /PRNewswire/ --

HIGHLIGHTS

  • Company achieved fourth-quarter global box office of $278 million, up 13% over the prior year.
  • IMAX domestic box office increased 17% in the second half of 2017, compared to an industry decline of 6%.
  • Installed 165 new IMAX® theater systems during 2017, bringing the Company's total commercial multiplex network to 1,272 theaters, 68% of which are in international markets.
  • Company signed agreements for 170 new theater systems in 2017, resulting in year-end backlog of 494 new systems, plus five upgrades.
  • SG&A, excluding stock-based compensation, was down 5% year-over-year to $90 million, following the Company's cost-reduction initiative.
  • Over the four-day Presidents' Day and Chinese New Year weekend, the Company achieved record February box office of $53 million, led by the release of Marvel Studios' Black Panther and three local-language titles released in China.

IMAX Corporation (NYSE: IMAX) today reported fourth-quarter 2017 revenue of $125.6 million and net income attributable to common shareholders of $4.8 million, or $0.08 per diluted share, which includes a one-time tax charge of $9.3 million ($0.14 per diluted share) associated with the recent U.S. tax reform and a $2.5 million ($0.04 per diluted share) charge associated with the Company's cost reduction exercise announced in June. Full-year 2017 revenue was $380.8 million and net income attributable to common shareholders was $2.3 million, or $0.04 per diluted share, which includes the one-time tax charge of $9.3 million ($0.14 per diluted share) and total restructuring charge of $16.2 million ($0.25 per diluted share).

IMAX Logo. (PRNewsFoto/IMAX Corporation)

Adjusted net income attributable to common shareholders for the fourth quarter was $21.8 million, or $0.34 per diluted share. Full-year 2017 adjusted net income attributable to common shareholders was $40.5 million, or $0.62 per diluted share. For reconciliations of reported results to non-GAAP financial results, and for the definition and reconciliation of Adjusted EBITDA per Credit Facility, please see the end of this press release.

"We saw tangible improvements to box office performance and operating leverage in the second half last year, largely the result of our implementing several initiatives aimed at refining our programming strategy and containing costs," said Richard L. Gelfond, IMAX CEO. "IMAX domestic box office increased 17% in the second half, compared to an exhibitor industry decline of 6%. In international markets, we grew box office 14% over the same period. We believe this underscores the IMAX consumer value proposition for compelling content and highlights the importance of analyzing our results separately from the overall industry's. Moreover, our growing international presence in markets such as Japan—a market that housed our single strongest-performing theater last year—continued to contribute meaningfully to our overall results."

Fourth-Quarter 2017 Results

U.S. Tax Cuts and Jobs Act (Tax Act) In the fourth quarter of 2017, IMAX incurred a discrete tax expense of $9.3 million, related to the enactment of the U.S. Tax Cuts and Jobs Act on Dec. 22, 2017. This non-recurring charge relates to the provisional re-measurement and write-down of the Company's U.S. deferred tax assets and liabilities, given the changes enacted by the Tax Act.

Network Update During the quarter, the Company installed 70 theaters, of which 69 were for new theater locations and one was an upgrade. The total IMAX theater network consisted of 1,370 systems as of Dec. 31, 2017, of which 1,272 were in commercial multiplexes. There were 499 theaters in backlog as of Dec. 31, 2017, compared to the 498 in backlog as of Dec. 31, 2016.

IMAX signed contracts for 23 new theaters across 12 countries in the fourth quarter of 2017. For a breakdown of theater system signings, installations, network and backlog by type for the fourth quarter of 2017, please see the end of this press release.

Box Office Update Gross box office from IMAX DMR® films increased by 13% to $278.1 million in the fourth quarter of 2017 from $246.5 million in the fourth quarter of 2016, resulting in higher DMR revenues. Gross box office per-screen for the fourth quarter of 2017 averaged $227,000 in comparison to $233,300 in the fourth quarter of 2016. Gross box office was generated primarily by the exhibition of 45 films (20 new and 25 carryovers), as compared to 24 films (17 new and 7 carryovers) exhibited in the fourth quarter of 2016.

Please reference the chart below for a breakout of box office and per-screen averages on a regional basis:

Box Office (M's)

Per Screen Average (000's)

Q4 2017

Q4 2016

Q4 2017

Q4 2016

Global

$ 278.1

$ 246.5

$ 227.0

$ 233.3

Domestic

116.9

101.0

286.1

255.4

Greater China

63.3

60.0

131.1

168.4

Other Intl.

97.9

85.5

290.2

280.5

FY 2017

FY 2016

FY 2017

FY 2016

Global

$ 976.5

$ 965.7

$ 838.4

$ 963.8

Domestic

357.8

368.5

883.4

934.9

Greater China

290.8

295.7

666.1

932.3

Other Intl.

327.9

301.5

1,014.7

1,037.2

Fourth-Quarter Segment Results

Network Business

  • Network business revenue was $53.8 million in the quarter, compared with $47.6 million in the prior-year period. Margins for the network business were 64.3% in the most recent quarter, compared to 65.8% in the prior-year period.
  • IMAX DMR revenues were $31.7 million in the fourth quarter of 2017, compared to $27.6 million in the fourth quarter of 2016. Gross margin for the IMAX DMR segment was 60.6%, compared to 60.8% in the prior-year comparative period.
  • Revenue from joint revenue-sharing arrangements was $20.7 million in the quarter, compared with $18.5 million in the prior-year comparative period. Gross margin for joint revenue-sharing arrangements was 67.8%, compared to 70.7% in the prior-year comparative period.

Theater Business

  • Theater business segment revenue was $55.5 million in the quarter, compared with $53.0 million in the prior-year comparative period.
  • The Company's gross margin on full, new sales and sales-type leases were 68.7% compared with 63.7% in the year-ago period, with the increase primarily a result of the deal-types for the systems recognized in the respective periods.
  • The Company expects to install approximately 145 new IMAX theater systems in 2018.

Fourth-Quarter Consolidated ResultsThe gross margin across all segments in the fourth quarter of 2017 was $60.1 million, or 48.0% of total revenue, compared to $55.3 million, or 51.7% of total revenue in the fourth quarter of 2016. Operating expenses (which include SG&A and R&D, and exclude stock-based compensation) were $27.3 million in the quarter, down 5% compared to $28.7 million in the fourth quarter of 2016.

Full-Year 2017 ResultsFull-year 2017 revenue was $380.8 million as compared to 2016 revenue of $377.3 million. Reported net income attributable to common shareholders was $2.3 million, or $0.04 per diluted share, as compared to $28.8 million or $0.42 per diluted share in 2016. Adjusted net income attributable to common shareholders was $40.5 million as compared to $50.0 million in 2016, or $0.62 per diluted share as compared to $0.73 per diluted share in 2016. Adjusted EBITDA per the Credit Facility, excluding the Company's investment in the television series Marvel's Inhumans, was $126.2 million in 2017 as compared to $121.9 million in 2016. The Company also reported a global 2017 per-screen average of $838,373, as compared to $963,800 in the prior year.

The full-year systems installation total was 170 theater systems, of which 5 were upgrades, compared with 182 and 16, respectively, in the prior-year period. Continuing to build upon the Company's record signings momentum from 2016, IMAX signed contracts for 177 theaters in 2017, across 35 countries, resulting in 499 theater systems in backlog as of Dec. 31, 2017, compared to 498 theater systems in backlog as of Dec. 31, 2016. The Company's top three markets for signings during 2017 were China, Germany and India. For a breakdown of theater system signings, installations, network and backlog by type, please see the end of this press release.

"As we look to 2018, our primary focus is on expanding the earnings power of our core business," said Gelfond. "We believe the combination of the initiatives we implemented last year, coupled with a growing international presence and reduced spend on non-core businesses and R&D, should help facilitate operating leverage in the future. Our overarching efforts this year are aimed at growing the network, controlling costs and generating more box office across our theaters. And I am pleased to say that 2018 is off to a solid start. We recently achieved record box office in February, led by Black Panther, which did $35 million in IMAX box office over the four-day opening weekend. In China, we exhibited three local-language titles during the Chinese New Year period and grew box office 60%, compared to the prior years' holiday."

Supplemental MaterialsFor more information about the Company's results, please refer to the IMAX Investor Relations website located at investors.imax.com.

Investor Relations Website and Social MediaOn a weekly basis, the Company posts quarter-to-date box office results on the IMAX Investor Relations website located at www.imax.com/content/investor-relations. The Company expects to provide such updates on Friday of each week, although the Company may change this timing without notice. Results will be displayed with a one-week lag. In addition, the Company maintains a Twitter account: @IMAX_Investors. The Company intends to use Twitter to disclose the box office information, as well as other information that may be of interest to the Company's investor community.

The information posted on the Company's website and/or via its Twitter account may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company's website and its Twitter account in addition to the Company's press releases, SEC filings and public conference calls and webcasts.

Conference CallThe Company will host a conference call today at 4:30PM ET to discuss its fourth quarter and full-year 2017 financial results. This call is being webcast by Nasdaq and can be accessed at investors.imax.com. To access the call via telephone, interested parties in the US and Canada should dial (888) 394-8218 approximately 5 to 10 minutes before the call begins. Other international callers should dial (647) 484-0475. The conference ID for the call is 8365766. A replay of the call will be available via webcast at investors.imax.com or via telephone by dialing (888) 203-1112 (US and Canada), or (647) 436-0148 (international). The Conference ID for the telephone replay is 8365766.

About IMAX Corporation IMAX, an innovator in entertainment technology, combines proprietary software, architecture and equipment to create experiences that take you beyond the edge of your seat to a world you've never imagined. Top filmmakers and studios are utilizing IMAX theaters to connect with audiences in extraordinary ways, and, as such, IMAX's network is among the most important and successful theatrical distribution platforms for major event films around the globe.

IMAX is headquartered in New York, Toronto and Los Angeles, with additional offices in London, Dublin, Tokyo, and Shanghai. As of December 31, 2017, there were 1,370 IMAX theater systems (1,272 commercial multiplexes, 12 commercial destinations, 86 institutional) operating in 75 countries. On Oct. 8, 2015, shares of IMAX China, a subsidiary of IMAX Corp., began trading on the Hong Kong Stock Exchange under the stock code "HK.1970."

IMAX®, IMAX® 3D, IMAX DMR®, Experience It In IMAX®, An IMAX 3D Experience®, The IMAX Experience®, IMAX Is Believing® and IMAX nXos® are trademarks of IMAX Corporation. More information about the Company can be found at www.imax.com. You may also connect with IMAX on Facebook (www.facebook.com/imax), Twitter (www.twitter.com/imax) and YouTube (www.youtube.com/imaxmovies).

This press release contains forward looking statements that are based on IMAX management's assumptions and existing information and involve certain risks and uncertainties which could cause actual results to differ materially from future results expressed or implied by such forward looking statements. Important factors that could affect these statements include, but are not limited to, references to future capital expenditures (including the amount and nature thereof), business and technology strategies and measures to implement strategies, competitive strengths, goals, expansion and growth of business, operations and technology, plans and references to the future success of IMAX Corporation together with its consolidated subsidiaries (the "Company") and expectations regarding the Company's future operating, financial and technological results. These forward-looking statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the expectations and predictions of the Company is subject to a number of risks and uncertainties, including, but not limited to, risks associated with investments and operations in foreign jurisdictions and any future international expansion, including those related to economic, political and regulatory policies of local governments and laws and policies of the United States and Canada; risks related to the Company's growth and operations in China; the performance of IMAX DMR films; the signing of theater system agreements; conditions, changes and developments in the commercial exhibition industry; risks related to currency fluctuations; the potential impact of increased competition in the markets within which the Company operates; competitive actions by other companies; the failure to respond to change and advancements in digital technology; risks relating to recent consolidation among commercial exhibitors and studios; risks related to new business initiatives; conditions in the in-home and out-of-home entertainment industries; the opportunities (or lack thereof) that may be presented to and pursued by the Company; risks related to cyber-security; risks related to the Company's inability to protect the Company's intellectual property; general economic, market or business conditions; the failure to convert theater system backlog into revenue; changes in laws or regulations; the failure to fully realize the projected cost savings and benefits from the Company's restructuring initiative; and other factors, many of which are beyond the control of the Company. These factors, other risks and uncertainties and financial details are discussed in IMAX's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

For additional information please contact:

Investors:

Michael K. Mougias

212-821-0187

[email protected]

Business Media:

Sloane & Company, New York

Whit Clay

212-446-1864

[email protected]

Media:

IMAX Corporation, New York

Ann Sommerlath

212-821-0155

[email protected]

Entertainment Media:

Principal Communications Group, Los Angeles

Melissa Zuckerman/Paul Pflug

323-658-1555

[email protected]

[email protected]

Additional Information

IMAX Theater Information

December 31, 2017

Years Ended December 31,

2017

2016

Theater System Signings:

Full new sales and sales-type lease arrangements

85

61

New traditional joint revenue sharing arrangements

35

246

New hybrid joint revenue sharing arrangements

50

7

Total new theaters

170

314

Upgrades of IMAX theater systems

7

5

Total Theater Signings

177

319

Years Ended December 31,

2017

2016

Theater System Installations:

Full new sales and sales-type lease arrangements

60

56

New traditional joint revenue sharing arrangements

86

76

New hybrid joint revenue sharing arrangements

19

33

Short-term operating lease arrangement

-

1

Total new theaters

165

166

Upgrades of IMAX theater systems

5

16

Total Theater Installations

170

182

As of December 31,

Theater Backlog:

2017

2016

New sales and sales-type lease arrangements

161

140

New joint revenue sharing arrangements

Hybrid arrangements

121

92

Traditional arrangements

212

263

Total new theaters

494

495

Upgrades of IMAX theater systems

5

3

Total Theater Backlog

499

498

As of December 31,

Theater Network:

2017

2016

Commercial Multiplex Theaters:

Sales and sales-type lease arrangements

525

467

Joint revenue sharing arrangements

747

640

Total Commercial Multiplex Theaters

1,272

1,107

Commercial Destination

12

16

Institutional

86

92

Total Theater Network

1,370

1,215

Additional Information (continued)

2018 DMR Films:

To date, the Company has announced the following 31 DMR titles to be released in 2018 to the IMAX theater network. The Company remains in active negotiations with all of the major Hollywood studios, as well as international studios, for additional films to fill out its short and long-term film slate, and anticipates that the number of IMAX DMR films to be released to the IMAX theater network in 2018 will be similar to the 60 IMAX DMR films released to the IMAX theater network in 2017.

(1) The Commuter: The IMAX Experience (Lionsgate Entertainment Inc., January 2018); (2) 12 Strong: The IMAX Experience (Warner Bros. Pictures, January 2018); (3) Padmaavat: The IMAX Experience (Viacom 18 Motion Pictures and Paramount Pictures, January 2018, India plus limited Domestic footprint and International markets); (4) Maze Runner: The Death Cure: The IMAX Experience (20th Century Fox, January 2018);(5) Fifty Shades Freed: The IMAX Experience (Universal Pictures, February 2018); (6) Monster Hunt 2: The IMAX Experience (Edko Films, February 2018, China only); (7) Detective Chinatown 2: The IMAX Experience (WanDa Pictures, February 2018, China only); (8) Operation Red Sea: The IMAX Experience (Bona Film Group, February 2018, China only); (9) Marvel's Black Panther: The IMAX Experience (Walt Disney Studios, February 2018);(10) Red Sparrow: The IMAX Experience (20th Century Fox, March 2018); (11) A Wrinkle in Time: The IMAX Experience (Walt Disney Studios, March 2018); (12) Tomb Raider: The IMAX Experience (Warner Bros. Pictures, March 2018); (13) Pacific Rim Uprising: The IMAX Experience (Warner Bros. Pictures, March 2018); (14) Ready Player One: The IMAX Experience (Warner Bros. Pictures, March 2018); (15) Rampage: The IMAX Experience (Warner Bros. Pictures, April 2018); (16) Avengers: Infinity War: The IMAX Experience (Walt Disney Studios, May 2018, most International markets – April 2018); (17) Deadpool 2: The IMAX Experience (20th Century Fox, May 2018, select markets only); (18) Solo: A Star Wars Story: The IMAX Experience (Walt Disney Studios, May 2018); (19) The Incredibles 2: The IMAX Experience (Walt Disney Studios, June 2018); (20) Jurassic World: Fallen Kingdom: The IMAX Experience (Universal Pictures, June 2018); (21) Ant-Man and the Wasp: The IMAX Experience (Walt Disney Studios, June 2018, US markets - July 2018); (22) Mission Impossible: Fallout: The IMAX Experience (Paramount Pictures, July 2018); (23) Predator: The IMAX Experience (20th Century Fox, August 2018); (24) The Darkest Minds: The IMAX Experience (20th Century Fox, September 2018); (25) Robin Hood: The IMAX Experience (Lionsgate Entertainment Inc., September 2018); (26) Venom: The IMAX Experience (Sony Pictures Entertainment, October 2018); (27) X-Men: Dark Phoenix: The IMAX Experience (20th Century Fox, November 2018); (28) Fantastic Beasts: The Crimes of Grindelwald: The IMAX Experience (Warner Bros. Pictures, November 2018); (29) Ralph Breaks the Internet: Wreck-It-Ralph 2: The IMAX Experience (Walt Disney Studios, December 2018, select markets); (30) Alita: Battle Angel: An IMAX Experience (20th Century Fox, December 2018); and (31) Aquaman: The IMAX Experience (Warner Bros. Pictures, December 2018).

In addition, the Company in conjunction with Panda Productions will be releasing an IMAX original production, Pandas, in April 2018.

IMAX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

In accordance with United States Generally Accepted Accounting Principles

(In thousands of U.S. dollars, except per share amounts)

Three Months

Years Ended

Ended December 31,

Ended December 31,

2017

2016

2017

2016

Revenues

Equipment and product sales

$

39,700

$

41,318

$

103,294

$

122,382

Services

62,330

44,009

195,594

166,862

Rentals

21,138

18,777

72,281

77,315

Finance income

2,384

2,509

9,598

9,500

Other

-

300

-

1,275

125,552

106,913

380,767

377,334

Costs and expenses applicable to revenues

Equipment and product sales

15,819

20,605

48,172

69,680

Services

40,951

25,263

120,629

83,780

Rentals

8,634

5,719

26,720

21,086

Other

-

-

-

110

65,404

51,587

195,521

174,656

Gross margin

60,148

55,326

185,246

202,678

Selling, general and administrative expenses

25,329

32,039

110,400

124,745

(including share-based compensation expense of $4.2 million and $20.4 million for the three months and year ended December 31, 2017, respectively (2016 - expense of $8.0 million and $30.5 million, respectively))

Research and development

6,217

4,712

20,855

16,315

Amortization of intangibles

837

542

3,019

2,079

Receivable provisions, net of recoveries

559

323

2,647

954

(Impairment recoveries) asset impairments

-

(1,000)

1,225

417

Exit costs, restructuring charges and associated impairments

2,479

-

16,174

-

Income from operations

24,727

18,710

30,926

58,168

Interest income

266

273

1,027

1,490

Interest expense

(524)

(480)

(1,942)

(1,805)

Income from operations before income taxes

24,469

18,503

30,011

57,853

Provision for income taxes

(15,905)

(6,577)

(16,790)

(16,212)

Gain (loss) from equity-accounted investments, net of tax

134

150

(703)

(2,321)

Net income

8,698

12,076

12,518

39,320

Less: net income attributable to non-controlling interests

(3,867)

(3,131)

(10,174)

(10,532)

Net income attributable to common shareholders

$

4,831

$

8,945

$

2,344

$

28,788

Net income per share attributable to common shareholders - basic and diluted:

Net income per share – basic

$

0.08

$

0.14

$

0.04

$

0.43

Net income per share – diluted

$

0.08

$

0.13

$

0.04

$

0.42

Weighted average number of shares outstanding (000's):

Basic

64,658

66,152

65,380

67,575

Fully Diluted

64,790

66,950

65,540

68,263

Additional Disclosure:

Depreciation and amortization(1)

$

27,040

$

12,306

$

66,807

$

46,485

(1) Includes $0.2 million and $0.6 million of amortization of deferred financing costs charged to interest expense for the three months and year ended December 31, 2017 (2016 - $0.1 million and $0.5 million, respectively).

IMAX CORPORATION

CONSOLIDATED BALANCE SHEETS

In accordance with United States Generally Accepted Accounting Principles

(In thousands of U.S. dollars)

As at December 31,

2017

2016

Assets

Cash and cash equivalents

$

158,725

$

204,759

Accounts receivable, net of allowance for doubtful accounts of $1,613 (December 31, 2016 — $1,250)

130,546

96,349

Financing receivables

129,494

122,125

Inventories

30,788

42,121

Prepaid expenses

7,549

6,626

Film assets

5,026

16,522

Property, plant and equipment

276,781

245,415

Other assets

26,757

33,195

Deferred income taxes

30,708

20,779

Other intangible assets

31,211

30,416

Goodwill

39,027

39,027

Total assets

$

866,612

$

857,334

Liabilities

Bank indebtedness

$

25,357

$

27,316

Accounts payable

24,235

19,990

Accrued and other liabilities

100,140

93,208

Deferred revenue

113,270

90,266

Total liabilities

263,002

230,780

Commitments and contingencies

Non-controlling interests

1,353

4,980

Shareholders' equity

Capital stock common shares — no par value. Authorized — unlimited number.

64,902,201 — issued and 64,695,550 — outstanding (December 31, 2016 — 66,224,467 — issued and 66,159,902 — outstanding)

445,797

439,213

Less: Treasury stock, 206,651 shares at cost (December 31, 2016 — 64,565)

(5,133)

(1,939)

Other equity

175,300

177,304

Accumulated deficit

(87,592)

(47,366)

Accumulated other comprehensive loss

(626)

(5,200)

Total shareholders' equity attributable to common shareholders

527,746

562,012

Non-controlling interests

74,511

59,562

Total shareholders' equity

602,257

621,574

Total liabilities and shareholders' equity

$

866,612

$

857,334

IMAX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

In accordance with United States Generally Accepted Accounting Principles

(In thousands of U.S. dollars)

Years Ended December 31,

2017

2016

Cash provided by (used in):

Operating Activities

Net income

$

12,518

$

39,320

Adjustments to reconcile net income to cash from operations:

Depreciation and amortization

66,807

46,485

Write-downs, net of recoveries

29,568

5,940

Change in deferred income taxes

(4,017)

4,940

Stock and other non-cash compensation

24,075

31,586

Unrealized foreign currency exchange (gain) loss

(502)

462

Loss from equity-accounted investments

306

2,685

Gain on non-cash contribution to equity-accounted investees

397

(364)

Investment in film assets

(34,645)

(22,308)

Changes in other non-cash operating assets and liabilities

(9,141)

(30,874)

Net cash provided by operating activities

85,366

77,872

Investing Activities

Purchase of property, plant and equipment

(24,143)

(15,278)

Investment in joint revenue sharing equipment

(42,634)

(42,910)

Investment in new business ventures

(1,606)

(1,911)

Acquisition of other intangible assets

(5,214)

(4,787)

Net cash used in investing activities

(73,597)

(64,886)

Financing Activities

Repayment of bank indebtedness

(2,000)

(2,000)

Repurchase of common shares

(46,140)

(116,518)

Settlement of restricted share units and options

(20,331)

(17,889)

Exercise of stock options

16,668

13,113

Treasury stock repurchased for future settlement of restricted share units

(5,133)

(1,996)

Taxes withheld and paid on employee stock awards vested

(600)

(528)

Taxes paid on secondary sales and repatriation dividend

-

(2,443)

Issuance of subsidiary shares to non-controlling interests - private offering

-

2,479

Net cash used in financing activities

(57,536)

(125,782)

Effects of exchange rate changes on cash

(267)

106

Decrease in cash and cash equivalents during year

(46,034)

(112,690)

Cash and cash equivalents, beginning of year

204,759

317,449

Cash and cash equivalents, end of year

$

158,725

$

204,759

IMAX CORPORATION SELECTED FINANCIAL DATAIn accordance with United States Generally Accepted Accounting Principles (in thousands of U.S. dollars)

The Company has four primary reporting groups identified by nature of product sold or service provided: (1) Network Business, representing variable revenue generated by box-office results and which includes the reportable segments of IMAX DMR and contingent rent from the JRSAs and IMAX systems segments; (2) Theater Business, representing revenue generated by the sale and installation of theater systems and maintenance services, primarily related to the IMAX Systems and Theater System Maintenance reportable segments, and also includes fixed hybrid revenues and upfront installation costs from the JRSA segment; (3) New Business, which includes content licensing and distribution fees associated with our original content investments, virtual reality initiatives, IMAX Home Entertainment, and other business initiatives that are in the development and/or start-up phase, and (4) Other; which includes the film post-production and distribution segments and certain IMAX theaters that the Company owns and operates, camera rentals and other miscellaneous items.

Three Months

Years Ended

Ended December 31,

Ended December 31,

2017

2016

2017

2016

Revenue(1)

Network Business

IMAX DMR

$

31,717

$

27,636

$

108,853

$

106,403

Joint revenue sharing arrangements - contingent rent

20,741

18,506

70,444

73,500

IMAX systems - contingent rent

1,317

1,466

3,890

4,644

53,775

47,608

183,187

184,547

Theater Business

IMAX systems

Sales and sales-type leases

31,675

31,002

79,853

89,525

Ongoing fees and finance income

2,650

2,551

10,494

11,359

Joint revenue sharing arrangements – fixed fees

5,582

5,967

10,118

17,913

Theater system maintenance

11,924

10,399

45,383

40,430

Other theater

3,696

3,100

9,145

10,888

55,527

53,019

154,993

170,115

New Business

13,014

25

24,522

626

Other

Film distribution and post-production

1,803

4,346

13,172

14,127

Other

1,433

1,915

4,893

7,919

3,236

6,261

18,065

22,046

Total

$

125,552

$

106,913

$

380,767

$

377,334

Gross margin

Network Business

IMAX DMR

$

19,211

$

16,798

$

71,789

$

69,196

Joint revenue sharing arrangements – contingent rent

14,066

13,085

47,337

54,705

IMAX systems – contingent rent

1,317

1,466

3,890

4,644

34,594

31,349

123,016

128,545

Theater Business

IMAX systems

Sales and sales-type leases

19,449

17,993

47,639

44,788

Ongoing fees and finance income

2,513

2,381

10,095

10,660

Joint revenue sharing arrangements – fixed fees

1,462

2,036

2,349

5,132

Theater system maintenance

4,969

3,453

18,275

13,660

Other theater

883

937

1,965

1,930

29,276

26,800

80,323

76,170

New Business

(2,744)

(1,338)

(16,176)

(2,199)

Other

Film distribution and post-production

(744)

(2,210)

(1,006)

(180)

Other

(234)

725

(911)

342

(978)

(1,485)

(1,917)

162

Total

$

60,148

$

55,326

$

185,246

$

202,678

IMAX CORPORATION OTHER INFORMATION (in thousands of U.S. dollars)

Non-GAAP Financial Measures:

In this release, the Company presents adjusted net income, adjusted net income per diluted share, adjusted net income attributable to common shareholders, adjusted net income attributable to common shareholders per diluted share, EBITDA, Adjusted EBITDA per Credit Facility and Adjusted EBITDA per Credit Facility excluding "Marvel's Inhumans" as supplemental measures of performance of the Company, which are not recognized under U.S. GAAP.

The Company presents adjusted net income and adjusted net income per diluted share because it believes that they are important supplemental measures of its comparable controllable operating performance and it wants to ensure that its investors fully understand the impact of stock-based compensation (net of any related tax impact) and non-recurring charges on net income. In addition, the Company presents adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders per diluted share because it believes that they are important supplemental measures of its comparable financial results. Without the presentation of these adjusted presentation measures the Company believes it could potentially distort the analysis of trends in business performance, and it wants to ensure that its investors fully understand the impact of net income attributable to non-controlling interests, its stock-based and non-recurring charges in determining net income attributable to common shareholders. Management uses these measures to review operating performance on a comparable basis from period to period. However, these non-GAAP measures may not be comparable to similarly titled amounts reported by other companies. Adjusted net income, adjusted net income per diluted share, adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders per diluted share should be considered in addition to, and not as a substitute for, net income and net income attributable to common shareholders and other measures of financial performance reported in accordance with U.S. GAAP.

The Company is required to maintain a minimum level of "EBITDA", as such term is defined in the Company's credit agreement (and which is referred to herein as "Adjusted EBITDA per Credit Facility" or "Adjusted EBITDA per Credit Facility excluding Marvel's Inhumans", as the credit agreement includes additional adjustments beyond interest, taxes, depreciation and amortization). Adjusted EBITDA per Credit Facility and Adjusted EBITDA per Credit Facility excluding "Marvel's Inhumans" (each as defined below) should not be construed as substitutes for net income, operating income or other operating performance measures that are determined in accordance with U.S. GAAP. The Company believes that EBITDA, Adjusted EBITDA per Credit Facility and Adjusted EBITDA per Credit Facility excluding Marvel's Inhumans are relevant and useful information widely used by analysts, investors and other interested parties in the Company's industry.

Quarter Ended

Year Ended

Year Ended

December 31, 2017

December 31, 2017

(1)

December 31, 2016

(In thousands of U.S. Dollars)

Net income

$

8,698

$

12,518

$

39,320

Add (subtract):

Provision for income taxes

15,905

16,790

16,212

Interest expense, net of interest income

258

915

315

Depreciation and amortization, including film asset amortization

26,900

66,245

45,953

EBITDA

51,761

96,468

101,800

Exit costs, restructuring charges and associated impairments

2,479

16,174

Stock and other non-cash compensation

4,802

23,718

31,586

Write-downs, net of recoveries including asset impairments and

receivable provisions

3,948

24,015

5,940

(Gain) loss from equity accounted investments

(134)

703

2,321

Adjusted EBITDA before non-controlling interests

62,856

161,078

141,647

Adjusted EBITDA attributable to non-controlling interests(2)

(7,055)

(22,927)

(19,743)

Adjusted EBITDA per Credit Facility

$

55,801

$

138,151*

$

121,904

Adjusted EBITDA per Credit Facility, excluding impact from "Marvel's Inhumans"

$

42,361

$

126,158*

$

121,904

Adjusted revenues attributable to common shareholders (3)

$

113,285

$

340,460

$

339,868

Adjusted EBITDA margin, excluding impact from "Marvel's Inhumans"

37.4

%

37.1

%

35.9

%

*

Adjusted EBITDA per Credit Facility of $138.2 million includes the impact of the Company's investment in "Marvel's Inhumans", which resulted in a $13.0 million loss. However, as permitted by the Credit Facility, this loss was offset by addbacks of $13.3 million and $11.7 million for amortization and impairment charges, respectively, relating to the investment, the net effect of which was to increase Adjusted EBITDA per Credit Facility by $12.0 million. This investment represents the Company's first foray into a commercial television property, and therefore the Adjusted EBITDA per Credit Facility metric presented above may not be reflective of the Company's typical operational activity. Further, the Company does not yet know whether it will make similar investments in the future. As a result, the Company is also presenting Adjusted EBITDA per Credit Facility excluding the impact of "Marvel's Inhumans" to better facilitate comparisons to prior and future periods.

__________________

(1)

Ratio of funded debt calculated using twelve months ended EBITDA.

(2)

The Adjusted EBITDA calculation specified for purpose of the minimum Adjusted EBITDA covenant excludes the reduction in Adjusted EBITDA from the Company's non-controlling interests.

(3)

Quarter Ended

Year Ended

Year Ended

December 31, 2017

December 31, 2017

December 31, 2016

Total revenues

$

125,552

$

380,767

$

377,334

Greater China revenues

$

38,339

$

126,474

$

118,532

Non-controlling interest ownership percentage (4)

32.00%

31.87%

31.61%

Deduction for non-controlling interest share

of revenues

(12,268)

(40,307)

(37,466)

Adjusted revenues attributable to common

shareholders

$

113,285

$

340,460

$

339,868

(4)

Weighted average ownership percentage for change in non-controlling interest share

IMAX CORPORATION OTHER INFORMATION (in thousands of U.S. dollars, except per share amounts)

Adjusted Net Income and Adjusted Diluted Per Share Calculations – Quarter Ended December 31, 2017 vs. 2016:

The Company reported net income of $8.7 million or $0.13 per basic and diluted share for the quarter ended December 31, 2017 as compared to net income of $12.1 million, or $0.18 per basic and diluted share for the quarter ended December 31, 2016.

Net income for the quarter ended December 31, 2017 includes a $4.9 million charge or $0.08 per diluted share (2016 — $8.0 million or $0.13 per diluted share) for stock-based compensation and a $2.5 million charge, or $0.04 per diluted share for exit costs, restructuring charges and associated impairments (2016 - $nil). In the quarter ended December 31, 2017, the Company also recognized a $9.3 million, or $0.14 per diluted share, non-recurring tax charge as the Company re-measured its deferred tax assets and liabilities as of the date of enactment of the recently passed U.S Tax Act.

Adjusted net income, which consists of net income excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the related tax impact of these adjustments, and tax charge from the provisional re-measurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act was $25.7 million or $0.40 per diluted share for the quarter ended December 31, 2017 as compared to adjusted net income of $17.7 million or $0.27 per diluted share for the quarter ended December 31, 2016.

The Company reported net income attributable to common shareholders of $4.8 million, or $0.08 per basic and diluted share for the quarter ended December 31, 2017 (2016 — $8.9 million, or $0.14 per basic and $0.13 per diluted share).

Adjusted net income attributable to common shareholders, which consists of net income attributable to common shareholders excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the related tax impact of these adjustments, and tax charge from the provisional re-measurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act, was $21.8 million or $0.34 per diluted share for the quarter ended December 31, 2017 as compared to adjusted net income attributable to common shareholders of $14.5 million or $0.22 per diluted share for the quarter ended December 31, 2016.

A reconciliation of net income and net income attributable to common shareholders, the most directly comparable U.S. GAAP measure, to adjusted net income, adjusted net income per diluted share, adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders per diluted share is presented in the table below:

Quarter Ended December 31,

2017

2016

Net Income

Diluted EPS

Net Income

Diluted EPS

Reported net income

$

8,698

$

0.13

$

12,076

$

0.18

(1)

Adjustments:

Stock-based compensation

4,857

0.08

8,038

0.13

Exit costs, restructuring charges and associated impairments

2,479

0.04

-

-

Tax impact on items listed above

360

0.01

(2,389)

(0.04)

Impact of enactment of U.S. Tax Act

9,323

0.14

-

-

Adjusted net income

25,717

0.40

17,725

0.27

(1)

Net income attributable to non-controlling interests

(3,867)

(0.06)

(3,131)

(0.05)

Stock-based compensation (net of tax of less than $0.1

million and less than $0.1 million, respectively)

(76)

-

(112)

-

Exit costs, restructuring charges and associated impairments

(net of tax of $nil)

(2)

-

-

-

Adjusted net income attributable to common shareholders

$

21,772

$

0.34

$

14,482

$

0.22

(1)

Weighted average diluted shares outstanding

64,790

66,950

Adjusted Net Income and Adjusted Diluted Per Share Calculations – Year Ended December 31, 2017 vs. 2016:

The Company reported net income of $12.5 million or $0.19 per basic and diluted share for the year ended December 31, 2017 as compared to net income of $39.3 million, or $0.58 per basic and diluted share, for the year ended December 31, 2016.

Net income for the year ended December 31, 2017 includes a $22.7 million charge or $0.35 per diluted share (2016 — $30.5 million or $0.45 per diluted share) for stock-based compensation and a $16.2 million charge, or $0.25 per diluted share for exit costs, restructuring charges and associated impairments (2016 - $nil). In 2017, the Company also recognized a $9.3 million, or $0.14 per diluted share, non-recurring tax charge as the Company re-measured its deferred tax assets and liabilities as of the date of enactment of the recently passed Tax Act.

Adjusted net income, which consists of net income excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the related tax impact of these adjustments, and tax charge from the provisional re-remeasurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act, was $51.5 million or $0.79 per diluted share for the year ended December 31, 2017 as compared to adjusted net income of $61.1 million or $0.90 per diluted share for the year ended December 31, 2016.

The Company reported net income attributable to common shareholders of $2.3 million, or $0.04 per basic and diluted share for the year ended December 31, 2017 (2016 — $28.8 million, or $0.43 per basic share and $0.42 per diluted share).

Adjusted net income attributable to common shareholders, which consists of net income attributable to common shareholders excluding the impact of stock-based compensation, exit costs, restructuring charges and associated impairments, the related tax impact of these adjustments, and tax charge from the provisional re-remeasurement of U.S. deferred tax assets and liabilities given changes enacted by the Tax Act, was $40.5 million or $0.62 per diluted share for the year ended December 31, 2017 as compared to adjusted net income attributable to common shareholders of $50.0 million or $0.73 per diluted share for the year ended December 31, 2016.

A reconciliation of net income and net income attributable to common shareholders, the most directly comparable U.S. GAAP measure, to adjusted net income, adjusted net income per diluted share, adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders per diluted share is presented in the table below:

Year Ended December 31,

2017

2016

Net Income

Diluted EPS

Net Income

Diluted EPS

Reported net income

$

12,518

$

0.19

$

39,320

$

0.58

Adjustments:

Stock-based compensation

22,653

0.35

30,523

0.45

Exit costs, restructuring charges and associated impairments

16,174

0.25

-

-

Tax impact on items listed above

(9,218)

(0.14)

(8,783)

(0.13)

Impact of enactment of U.S. Tax Act

9,323

0.14

-

-

Adjusted net income

51,450

0.79

61,060

0.90

Net income attributable to non-controlling interests

(10,174)

(0.16)

(10,532)

(0.16)

Stock-based compensation (net of tax of $0.2 million,

and $0.2 million, respectively)

(620)

(0.01)

(533)

(0.01)

Exit costs, restructuring charges and associated impairments

(net of tax of $0.1 million)

(181)

-

-

-

Adjusted net income attributable to common shareholders

$

40,475

$

0.62

$

49,995

$

0.73

Weighted average diluted shares outstanding

65,540

68,263

Free Cash Flow:

Free cash flow is defined as cash provided by operating activities minus cash used in investing activities (from the consolidated statements of cash flows). Cash provided by operating activities consist of net income, plus depreciation and amortization, plus the change in deferred income taxes, plus other non-cash items, plus changes in working capital, less investment in film assets, plus other changes in operating assets and liabilities. Cash used in investing activities includes capital expenditures, acquisitions and other cash used in investing activities. Management views free cash flow, a non-GAAP measure, as a measure of the Company's after-tax cash flow available to reduce debt, add to cash balances, and fund other financing activities. Free cash flow does not represent residual cash flow available for discretionary expenditures. A reconciliation of cash provided by operating activities to free cash flow is presented in the table below:

For the

For the

Three months ended

Twelve months ended

December 31, 2017

December 31, 2017

Net cash provided by operating activities

$

21,947

$

85,366

Net cash used in investing activities

(16,264)

(73,597)

Net cash flow

$

5,683

$

11,769

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/imax-corporation-reports-fourth-quarter-and-full-year-2017-results-300605139.html

SOURCE IMAX Corporation

Categories

Press Releases

Next Articles